GBA Presents: RADIO SAVANT-!

stonedinvestor said:
Shroom stock!

Mind Medicine initiated with an Outperform at Oppenheimer 16:05 MNMD Oppenheimer analyst…
More...
Lets see... it was about $14 at the time... and hmmmm... who would be the lead underwriter for this 50% dilution yesterday?

Hmmmm?

Can they lock that analyst up?
I mean he basically f'd retail investors out of about $340M dollars as best as I can tell.
Oh... maybe he didn't know.
Right.

Steal a can of soup to feed your family, its jail for a year and a lifetime record that relegates you to a minimum wage job at MCD for the rest of your life.... but steal $340M.... year end bonus, hookers, and blow.
 
But daddy needs new shoes....

upload_2022-9-29_11-34-4.jpeg

Issue an upgrade!!!
 
vanzandt said:
Stoney!!!!
I own tons of this.
Should I sell?
More...

WHERE IS STONEY?!:mad:

It's no fun to gloat w/o Stoney to gloat at.

Bull market or bear market....
VZ does it again.
>>>>Keeping GBA afloat in times of turmoil.

$17--->$32
:wtf::p:cool:

Amylyx Pharmaceuticals’ ALS Drug Wins FDA Approval. Shares soar.
150x-1.jpg

By
Fiona Rutherford

September 29, 2022, 9:11 PM UTC

Amylyx Pharmaceuticals Inc. won regulatory approval for its controversial treatment for amyotrophic lateral sclerosis, making it the third major medicine authorized in the US to slow the disease.

The treatment, to be called Relvyrio in the US, was approved despite uncertainty about its level of effectiveness in a clinical trial, the Food and Drug Administration said Thursday in a statement, but “given the serious and life-threatening nature of ALS and the substantial unmet need, this level of uncertainty is acceptable in this instance,” the agency said. The shares rose as much as 14% in trading after US markets closed.
 
Good Morning Everyone.-

Do we have any ET'ers from FLA? How re you making out? Big Pete's Hawaiian set up outside his house made it through the storm pretty good. Closer to the water it does not look good at all.

Now Ian takes dead aim at my son in Charleston. They have had no school for 2 days and are in their dorms.... I told him to gather food and water & keep his cell phone charged.-

LETS GET THIS RALLY STARTED TODAY --!

My computers have Sept 30 as lift off day why I have no idea. Do I even believe the computer -- No. /////////

I don't have a lot of names lined up because I have been very busy the last few days--

1> CFLT this is the one that wants to go up.
 
Citi opens 'positive 90-day Catalyst Watches' on four biotech names Citi analyst Yigal Nochomovitz opens "positive 90-day Catalyst Watches" on four biotech names: Apellis Pharmaceuticals (APLS), Arcus Biosciences (RCUS), Eiger BioPharmaceuticals (EIGR) and Merus (MRUS). All four have catalysts in Q4 and offer good risk/reward profiles, Nochomovitz tells investors in a research note. The analyst keeps Buy ratings on all four names.

We like Merus (MRUS) have used it twice as a gummy.
 
Scorpio Tankers purchases 225,000 of its common shares in the open market 16:46 STNG On September 29, the company purchased 225,000 of its common shares in the open market at an average price of $40.80 per share as part of the company's securities repurchase program.

We like STNG and Golar GLNG
 
:thumbsdown:Micron says shipments well below end-market consumption 16:58 MU Says pricing market is aggressive. Says expects weak first half of FY23 followed by strong second half. Says supply growth exceeding demand growth in FY22. Says spending on machinery to drop 50% in FY23. Says reducing capacity utilization to cut supply. Says production slowdown to hurt near-term profitability.

:thumbsup:Microsoft resumed with an Outperform at Raymond James 16:25 MSFT Raymond James analyst Andrew Marok resumed coverage of Microsoft with an Outperform rating and $300 price target. He sees Microsoft having "a collection of sustainable advantages," including strong positioning in public cloud, gaming and digital advertising; scale advantages from years of investment; deep relationships with enterprise software buyers; "essentially universal brand recognition"; and a position as a "low risk" vendor who can take share regardless of, or perhaps especially during, soft economic periocs, Marok tells investors.
 
SoftBank cuts 30% of Vision Fund workforce, FT reports 13:58 SFTBY SoftBank has slashed 30% of its workforce at its flagship Vision Funds as it aims to dramatically reduce costs after a severe tech downturn caused it to suffer record quarterly losses, the Financial Times' Anna Gross reports. The conglomerate began telling employees about forthcoming layoffs on Thursday, with 150 people in the Vision Fund unit, which boasts about 500 staff, set to lose their positions, the author says, citing people briefed on the decision.
 
stonedinvestor said:
Good Morning Everyone.-

Do we have any ET'ers from FLA? How re you making out? Big Pete's Hawaiian set up outside his house made it through the storm pretty good. Closer to the water it does not look good at all.

Now Ian takes dead aim at my son in Charleston. They have had no school for 2 days and are in their dorms.... I told him to gather food and water & keep his cell phone charged.-

LETS GET THIS RALLY STARTED TODAY --!

My computers have Sept 30 as lift off day why I have no idea. Do I even believe the computer -- No. /////////

I don't have a lot of names lined up because I have been very busy the last few days--

1> CFLT this is the one that wants to go up.
More...
Stoney!!!
Nike is at $84

The children Stoney!
You're wiping them out.
:cool:
 
You must log in or register to reply here.
Back
Top